Transcatheter chemoembolization of unresectable hepatocellular carcinoma: Current knowledge and future directions

Digestive Diseases

Volumn 27, Issue 2, 2009, Pages 157-163

  Maleux, Geert ^a   Van Malenstein, Hannah ^a   Vandecaveye, Vincent ^a   Heye, Sam ^a   Vaninbroukx, Johan ^a   Nevens, Frederik ^a   Verslype, Chris ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Embolization; Interventional procedure; Liver

Indexed keywords

ANTIBIOTIC AGENT; CISPLATIN; DOXORUBICIN; MITOMYCIN C;

CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHOLECYSTITIS; GOLD STANDARD; HEPATORENAL SYNDROME; HUMAN; LIVER ABSCESS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER GRAFT; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEPTICEMIA;

CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CHEMOEMBOLIZATION, THERAPEUTIC; HUMANS; LIVER NEOPLASMS;

EID: 67650931600     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000218348     Document Type: Review

References (33)

1. Bruix J, Sala M, Llovet JM: Chemoemboliza tion for hepatocellular carcinoma. Gastro enterology 2004;127:S179S188.
2. Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takshima S: Hepatic artery embolization in 120 patients with unresect able hepatoma. Radiology 1983; 148: 397401.
3. Brown DB, Gould JE, Gervais DA, GoldbergSN, Murthy R, Millward SF, Rilling WS, Ge schwind JF, Salem R, Vedantham S, Cardella JF, Soulen MC: Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. J Vasc IntervRadiol 2007;18:14691478.
4. Llovet JM, Real MI, Montana X, et al: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with nresectable hepatocellular carcinoma: a andomised controlled trial. Lancet 2002; 59:17341739.
5. Lo CM, Ngan H, Tso WK, et al: Randomized controlled trial of transarterial lipiodol che moembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 11641171.
6. Camma C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, Andreone P, Craxi A, Cottone M: Transarterial chemoemboli zation for unresectable hepatocellular carcinoma: metaanalysis of randomized controlled trials. Radiology 2002;224:4754.
7. Bharat A, Brown DB, Crippin JS, Gould JE,Lowell JA, Shenoy S, Desai NM, ChapmanWC: Preliver transplantation locoregional adjuvant therapy for hepatocellular carcinoma as a strategy to improve longterm survival. J Am Coll Surg 2006; 203: 411420.
8. Chapman WC, Doyle M, Stuart JE, Vachharajani N, Crippin JS, Anderson CD, Lowell JA, Shenoy S, Darcy MD, Brown DB: Outcomes of neoadjuvant transarterial chemo embolization to downstage hepatocellular carcinoma before liver transplantation. Ann Surg 2008;248:617625.
9. Chern MC, Chuang VP, Cheng T, Lin ZH,Lin YM: Transcatheter arterial chemoembo lization for advanced hepatocellular carcinoma with inferior vena cava and right atrial tumors. Cardiovasc Intervent Radiol 2008;31: 735744.
10. Kothary N, Weintraub JL, Susman J, Rund back JH: Transarterial chemoembolization for primary hepatocellular carcinoma in patients at high risk. J Vasc Interv Radiol 2007;18:15171527.
11. Tesdal IK, Wikstrom M, Flechtenmacher C, Filser T, Dueber C: Percutaneous treatment of hepatocellular carcinoma in patients with transjugular portosystemic shunts.Cardiovasc Intervent Radiol 2006; 29: 778784.
12. Kiely JM, Rilling WS, Touzios JG, Hieb RA,Franco J, Saeian K, Quebbeman EJ, Pitt HA:Chemoembolization in patients at high risk:results and complications. J Vasc Intervent Radiol 2006;17: 4753.
13. Georgiades CS, Hong K, D'Angelo M, Geschwind JF: Safety and efficacy of transarte rial chemoembolization in patients with un resectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol2005;16: 16531659.
14. Hunt SJ, Yu W, Weintraub J, Prince MR, Ko thary N: Radiologic monitoring of hepatocellular carcinoma tumor viability after transhepatic arterial chemoembolization: estimating the accuracy of contrastenhanced crosssectional imaging with histopathologic correlation. J Vasc Interv Radiol2009;20: 3038.
15. Song SY, Chung JW, Han JK, Lim HG, Koh YH, Park JH, Lee HS, Kim CY: Liver abscess after transcatheter oily chemoembolization for hepatic tumors: incidence, predisposing factors, and clinical outcome. J Vasc Interv Radiol 2001; 12: 313320.
16. Geschwind JF, Kaushik S, Ramsey DE,Choti MA, Fishman EK, Kobeiter H: Influence of a new prophylactic antibiotic therapy on the incidence of liver abscesses after chemoembolization treatment of liver tumors. J Vasc Interv Radiol 2002; 13: 11631166.
17. Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, Tibballs J, Meyer T, Patch DW, Burroughs AK: Transarte rial therapy for hepatocellular carcinoma:which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007;31: 625.
18. Ha BY, Ahmed A, Sze DY, Razavi MK, Simpson N, Keeffe EB, Nguyen MH: Longterm survival of patients with unresectable hepatocellular carcinoma treated with transcath eter arterial chemoinfusion. Aliment Pharmacol Ther 2007; 26:839846.
19. Kirchhoff TD, Bleck JS, Dettmer A, ChavanA, Rosenthal H, Merkesdal S, Frericks B,Zender L, Malek NP, Greten TF, Kubicka S,Manns MP, Galanski M: Transarterial che moembolization using degradable starch microspheres and iodized oil in the treatment of advanced hepatocellular carcinoma:evaluation of tumor response, toxicity, and survival. Hepatobiliary Pancreat Dis Int2007;6: 259266.
20. Brown DB, Pilgram TK, Darcy MD, Funda kowski CE, LiskerMelman M, Chapman WC, Crippin JS: Hepatic arterial chemoem bolization for hepatocellular carcinoma: comparison of survival rates with different embolic agents. J Vasc Interv Radiol 2005; 16:16611666.
21. Vandecaveye V, De Keyzer F, Dymarkowski S: Imaging and targeted agents in gastrointestinal cancers: overview on perfusion and diffusionweighted magnetic resonance imaging and angiogenesis inhibitors. Targ Oncol 2008;3:101110.
22. Li CP, Chao Y, Chen LT, Lee RC, Lee WP,Yuan JN, Yen SH, Lee SD: Fever after trans catheter arterial chemoembolization for he patocellular carcinoma: incidence and risk factor analysis. Scand J Gastroenterol 2008;43:992999.
23. Shim JH, Park JW, Choi JI, Kim HB, Lee WJ, Kim CM: Does postembolization fever after chemoembolization have prognostic significance for survival in patients with unresectable hepatocellular carcinoma? J Vasc IntervRadiol 2009; 20:209216.
24. Buijs M, Vossen JA, Frangakis C, Hong K, Georgiades CS, Chen Y, Liapi E, GeschwindJF: Nonresectable hepatocellular carcinoma: longterm toxicity in patients treated with transarterial chemoembolization single center experience. Radiology 2008;249:346 354.
25. Zhao H, Wang HQ, Fan QQ, Chen XX, Lou JY: Rare pulmonary and cerebral complications after transarterial chemoembolisation for hepatocellular carcinoma: a case report. World J Gastroenterol 2008;14:64256427.
26. Malagari K, Chatzimichael K, Alexopoulou E, Kelekis A, Hall B, Dourakis S, Delis S, Gouliamos A, Kelekis D: Transarterial che moembolization of unresectable hepatocel lular carcinoma with drugeluting beads: results of an openlabel study of 62 patients. Cardiovasc Intervent Radiol 2008;31:269
27. Malagari K, Alexopoulou E, Chatzimichael K, Hall B, Koskinas J, Ryan S, Gallardo E, Kelekis A, Gouliamos A Kelekis D: Trans catheter chemoembolization in the treatment of HCC in patients not eligible for curative treatments: midterm results of doxorubicinloaded DC bead. Abdom Imaging 2008;33: 512519.
28. Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, Ayuso C, Castells L, Montana X, Llovet JM, Bruix J: Chemoembolization of hepatocellular carcinoma with drugeluting beads: efficacy and doxorubicin pharmaco kinetics. J Hepatol 2007; 46:474481.
29. Poon RT, Tso WK, Pang RW, Ng KK, Woo R, Tai KS, Fan ST: A phase I/II trial of chemo embolization for hepatocellular carcinoma using a novel intraarterial drugeluting bead. Clin Gastroenterol Hepatol 2007; 5: 11001108.
30. Grosso M, Vignali C, Quaretti P, Nicolini A, Melchiorre F, Gallarato G, Bargellini I, Pe truzzi P, Massa Saluzzo C, Crespi S, Sarti I: Transarterial chemoembolization for hepa tocellular carcinoma with drugeluting mi crospheres: preliminary results from an Italian multicentre study. Cardiovasc Intervent Radiol 2008;31:11411149.
31. Lencioni R, Malagari K, Vogl T, et al: A randomised phase II trial of a drugeluting beads in the treatment of HCC by transcath eter arterial chemoembolisation. GI Cancer Symposium 2009, abstract 116.
32. Graf H, Jungst C, Straub G, Dogan S, Hoffmann RT, Jakobs T, Reiser M, Waggershauser T, Helmberger T, Walter A, Walli A, Seidel D, Goke B, Jungst D: Chemoembolization combined with pravastatin improvessurvival in patients with hepatocellular carcinoma. Digestion 2008; 78: 3438.
33. Ishida K, Hirooka M, Hiraoka A, Kumagi T,Uehara T, Hiasa Y, Horiike N, Onji M: Treatment of hepatocellular carcinoma using arterial chemoembolization with degradable starch microspheres and continuous arterial infusion of 5fluorouracil. Jpn J Clin Oncol2008;38:596603.